The effect of Crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure ☆
dc.contributor.author | Zick, Suzanna M. | en_US |
dc.contributor.author | Gillespie, Brenda | en_US |
dc.contributor.author | Aaronson, Keith D. | en_US |
dc.date.accessioned | 2014-02-11T17:57:02Z | |
dc.date.available | 2014-02-11T17:57:02Z | |
dc.date.issued | 2008-06 | en_US |
dc.identifier.citation | Zick, Suzanna M.; Gillespie, Brenda; Aaronson, Keith D. (2008). "The effect of Crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure ☆ ." European Journal of Heart Failure 10(6): 587-593. <http://hdl.handle.net/2027.42/102656> | en_US |
dc.identifier.issn | 1388-9842 | en_US |
dc.identifier.issn | 1879-0844 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/102656 | |
dc.description.abstract | Aim To examine whether hawthorn ( Crataegus Special Extract WS 1442 {CSE}) inhibits progression in heart failure (HF) patients. Methods We performed a retrospective analysis of data from the HERB CHF study in which patients with mild to moderate HF were randomised to either CSE 900 mg or placebo for 6months. The primary outcome was time to progression of HF (HF death, hospitalisation, or sustained increase in diuretics) as assessed by log‐rank tests and by Cox modelling. Results Progression of HF occurred in 46.6% of the CSE and 43.3% of the placebo groups (OR 1.14, 95% CI=0.56, 2.35: p =0.86). Patients receiving CSE were 3.9 times (95% CI=1.1−13.7: p =0.035) more likely to experience HF progression at baseline. In adjusted analysis, the risk of having early HF progression in the CSE group increased to 6.4 (95% CI=1.5, 26.5: p =0.011). In patients with LVEF≤35%, those taking CSE were at significantly greater risk (3.2, 95% CI=1.3, 8.3: p =0.02) than the placebo group. Conclusions CSE does not reduce heart failure progression in patients who have HF. CSE appears to increase the early risk of HF progression. | en_US |
dc.publisher | Alfa Omega Edetrice | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Crataegus Oxycantha | en_US |
dc.subject.other | Crataegus Special Extract WS 1442 | en_US |
dc.subject.other | Heart Failure Progression | en_US |
dc.subject.other | Hawthorn | en_US |
dc.title | The effect of Crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure ☆ | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Cardiovascular Medicine | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 18490196 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/102656/1/ejhf2008-04-008.pdf | |
dc.identifier.doi | 10.1016/j.ejheart.2008.04.008 | en_US |
dc.identifier.source | European Journal of Heart Failure | en_US |
dc.identifier.citedreference | Holubarsch C.J. WS C. Meinertz T. Crataegus extract WS1442 postpones cardiac death in patients with congestive heart failure class NYHA II‐III: a randomized placebo‐controlled, double‐blind trials in 2681 patients Late Breaking Clinical Trials‐3, Sessions 414–5 2007 New Orleans, LA American College of Cardiology (Abstract) | en_US |
dc.identifier.citedreference | Weihmayr T. Ernst E. Therapeutic effectiveness of Crataegus Fortschr Med 1996 114 27 29 | en_US |
dc.identifier.citedreference | Veveris M. Koch E. Chatterjee S.S. Crataegus Special Extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion Life Sci 2004 74 1945 1955 | en_US |
dc.identifier.citedreference | Krzeminski T. Chatterjee S.S. Ischemia and early reperfusion induced arrhythmias: beneficial effects of an extract of Crataegus oxyacantha L Pharm Pharmacol Lett 1993 3 45 48 | en_US |
dc.identifier.citedreference | Periera da Silva A. Rocha R. Silva C.M. Mira L. Duarte M.F. Florencio M.H. Antioxidants in medicinal plant extracts. A research study of the antioxidant capacity of Crataegus, Hamamelis and Hydrastis Phytother Res 2000 14 612 616 | en_US |
dc.identifier.citedreference | Bahorun T. Aumjaud E. Ramphul H. Phenolic constituents and antioxidant capacities of Crataegus monogyna (Hawthorn) callus extracts Nahrung 2003 47 191 198 | en_US |
dc.identifier.citedreference | Kirakosyan A. Seymour E. Kaufman P.B. Warber S. Bolling S. Chang S.C. Antioxidant capacity of polyphenolic extracts from leaves of Crataegus laevigata and Crataegus monogyna (Hawthorn) subjected to drought and cold stress J Agric Food Chem 2003 51 3973 3976 | en_US |
dc.identifier.citedreference | Zhang Z. Chang Q. Zhu M. Huang Y. Ho W.K.K. Chen Z.Y. Characterization of antioxidants present in hawthorn fruits J Nutr Biochem 2001 12 144 152 | en_US |
dc.identifier.citedreference | Chatterjee S.S. Koch E. Jaggy H. Krzeminski T. In vitro and in vivo studies on the cardioprotective action of oligomeric procyanidins in a Crataegus extract of leaves and blooms Arzneimittelforschung 1997 47 821 825 | en_US |
dc.identifier.citedreference | Schwitters B. OPC in Practice 1993 Rome Alfa Omega Edetrice | en_US |
dc.identifier.citedreference | Masquelier J. Beal J.L. Reinhard E. Pycnogenols: recent advances in the therapeutical activity of procyanidins Natural Products as Medicinal Agents: Plenary Lectures of the International Research Congress on Medicinal Plant Research, Strasbourg, July 1980 1981 Stuttgart Hippokrates Verlag | en_US |
dc.identifier.citedreference | Pittler M.H. Schmidt K. Ernst E. Hawthorn extract for treating chronic heart failure: meta‐analysis of randomized trials Am J Med 2003 114 665 674 | en_US |
dc.identifier.citedreference | Aaronson K.D. HERB‐CHF (Hawthorn Extract Randomized Blinded Chronic HF Study). Late‐breaking and Recent Clinical Trials. 8th Annual Scientific Meeting of the Heart Failure Society of America. Toronto, Ontario, Canada J Card Fail 2004 vol. 10 Supp (Abstract 2832) | en_US |
dc.identifier.citedreference | Aaronson K.D. Schwartz J.S. Chen T.M. Wong K.L. Goin J.E. Mancini D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation Circulation 1997 12 2660 2667 | en_US |
dc.identifier.citedreference | Holubarsch C.J. Colucci W.S. Meinertz T. Gaus W. Tendera M. Survival and prognosis: investigation of Crataegus Extract WS 1442 in congestive heart failure (SPICE)—rationale, study design and study protocol Eur J Heart Fail 2000 2 431 437 | en_US |
dc.identifier.citedreference | Johne A. Brockmoller J. Bauer S. Maurer A. Langheinrich M. Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) Clin Pharmacol Ther 1999 66 338 345 | en_US |
dc.identifier.citedreference | Yoo H.H. Lee M. Chung H.J. Lee S.K. Kim D.H. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P‐glycoprotein‐mediated drug efflux in human intestinal Caco‐2 cells J Agric Food Chem 2007 55 7620 7625 | en_US |
dc.identifier.citedreference | Lohner K. Schnabele K. Daniel H. Flavonoids alter P‐gp expression in intestinal epithelial cells in vitro and in vivo Mol Nutr Food Res 2007 51 293 300 | en_US |
dc.identifier.citedreference | Tankanow R. Tamer H.R. Streetman D.S. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha) J Clin Pharmacol 2003 43 637 642 | en_US |
dc.identifier.citedreference | Liang M. Xu W. Zhang W. Quantitative LC/MS/MS method and in vivo pharmacokinetic studies of vitexin rhamnoside, a bioactive constituent on cardiovascular system from hawthorn Biomed Chromatogr 2007 21 422 429 | en_US |
dc.identifier.citedreference | Zuo Z. Zhang L. Zhou L. Chang Q. Chow M. Intestinal absorption of hawthorn flavonoids—in vitro, in situ and in vivo correlations Life Sci 2006 79 2455 2462 | en_US |
dc.identifier.citedreference | Hilfiker‐Kleiner D. Landmesser U. Drexler H. Molecular mechanisms in heart failure J Am Coll Cardiol 2006 48 A56 A66 | en_US |
dc.identifier.citedreference | Kuster G.M. Kotlyar E. Rude M.K. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload Circulation 2005 111 420 427 | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.